Daptomycin Market: By Indication (Complicated Skin Structure Infections, Bacteremia, others), Age Group (Pediatric, Adult), Strength (350mg, 500mg) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2030
ID: MRFR/HC/8603-HCR | 120 Pages | Published By Kinjoll Dey on March 2023
Table of Contents
1. EXECUTIVE SUMMARY
1.1. Market Attractiveness Analysis
1.1.1. Global Daptomycin Market, by Indication
1.1.2. Global Daptomycin Market, by Age group
1.1.3. Global Daptomycin Market, by Strength
1.1.4. Global Daptomycin Market, by Region
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.3. Market Structure
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
3.5. Forecast Model
3.6. List of Assumptions
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.2.1. Increasing Complicated Skin & Skin Structure Infections
4.2.2. XXXXXX
4.2.3. XXXXXX
4.3. Restraints
4.3.1. XXXX
4.3.2. XXXX
4.4. Opportunities
4.4.1. Opportunity 1
5. MARKET FACTOR ANALYSIS
5.1. Value Chain Analysis/Supply Chain Analysis
5.2. Porter’s Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. Impact Analysis of COVID-19 on Anatomic Pathology Market
5.3.1. Impact on Supply Chain
5.3.2. Impact on Pricing
5.3.3. Impact in Major regions (Americas, Europe, Asia-Pacific, Middle East & Africa)
6. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY INDICATION
6.1. Overview
6.2. Complicated Skin Structure Infections
6.3. Bacteremia
6.4. Others
7. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY AGE GROUP
7.1. Overview
7.2. Pediatric
7.3. Adult
8. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY STRENGTH
8.1. Overview
8.2. 350 mg
8.3. 500 mg
9. GLOBAL DAPTOMYCIN MARKET SIZE ESTIMATION & FORECAST, BY REGION
9.1. Overview
9.2. Americas
9.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.2.3. Market Estimates & Forecast, by Strength, 2022–2030
9.2.4. Market Estimates & Forecast, by Region, 2022–2030
9.2.4.1. North America
9.2.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.2.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.2.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.2.4.1.4. Market Estimates & Forecast, by Country, 2022–2030
9.2.4.1.4.1. US
9.2.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.2.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.2.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.2.4.1.4.2. Canada
9.2.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.2.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.2.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030
9.2.4.2. Latin America
9.2.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.2.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.2.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3. Europe
9.3.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4. Market Estimates & Forecast, by Region, 2022–2030
9.3.4.1. Western Europe
9.3.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4. Market Estimates & Forecast, by Country, 2022–2030
9.3.4.1.4.1. Germany
9.3.4.1.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4.2. France
9.3.4.1.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4.3. UK
9.3.4.1.4.3.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.3.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.3.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4.4. Italy
9.3.4.1.4.4.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.4.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.4.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4.5. Spain
9.3.4.1.4.5.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.5.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.5.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.4.1.4.6. Rest of Western Europe
9.3.4.1.4.6.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.4.1.4.6.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.4.1.4.6.3. Market Estimates & Forecast, by Strength, 2022–2030
9.3.5. Eastern Europe
9.3.5.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.3.5.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.3.5.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4. Asia-Pacific
9.4.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4. Market Estimates & Forecast, by Country, 2022–2030
9.4.4.1. China
9.4.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4.2. India
9.4.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4.3. Japan
9.4.4.3.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.3.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.3.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4.4. Australia
9.4.4.4.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.4.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.4.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4.5. South Korea
9.4.4.5.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.5.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.5.3. Market Estimates & Forecast, by Strength, 2022–2030
9.4.4.6. Rest of Asia-Pacific
9.4.4.6.1. Market Estimates & Forecast, by Indication, 2022–2030
9.4.4.6.2. Market Estimates & Forecast, by Age group, 2022–2030
9.4.4.6.3. Market Estimates & Forecast, by Strength, 2022–2030
9.5. Middle East & Africa
9.5.1. Market Estimates & Forecast, by Indication, 2022–2030
9.5.2. Market Estimates & Forecast, by Age group, 2022–2030
9.5.3. Market Estimates & Forecast, by Strength, 2022–2030
9.5.4. Market Estimates & Forecast, by Region, 2022–2030
9.5.4.1. Middle East
9.5.4.1.1. Market Estimates & Forecast, by Indication, 2022–2030
9.5.4.1.2. Market Estimates & Forecast, by Age group, 2022–2030
9.5.4.1.3. Market Estimates & Forecast, by Strength, 2022–2030
9.5.4.2. Africa
9.5.4.2.1. Market Estimates & Forecast, by Indication, 2022–2030
9.5.4.2.2. Market Estimates & Forecast, by Age group, 2022–2030
9.5.4.2.3. Market Estimates & Forecast, by Strength, 2022–2030
10. COMPETITIVE LANDSCAPE
10.1. Overview
10.2. Competitive Analysis
10.3. Market Share Analysis
10.4. Major Growth Strategy in the Global Daptomycin Market
10.5. Competitive Benchmarking
10.6. Leading Player in terms of Number of Developments in Global Daptomycin Market
10.7. Key Developments & Growth Strategies
10.7.1. New Product Launch/Service Deployment
10.7.2. Merger & Acquisition
10.7.3. Joint Ventures
10.8. Major Players Financial Matrix & Market Ratio
10.8.1. Sales & Operating Income 2019
10.8.2. Major Players R&D Expenditure 2019
11. COMPANY PROFILES
11.1. Teva Pharmaceutical Industries Ltd.
11.1.1. Company Overview
11.1.2. Financial Overview
11.1.3. Indication Offered
11.1.4. Key Developments
11.1.5. SWOT Analysis
11.1.6. Key Strategies
11.2. Merck & Co.
11.3. Cipla
11.4. Pfizer
11.5. BE Pharmaceuticals
11.6. Dr. Reddy's Laboratories
11.7. Mylan
11.8. Fresenius Kabi
11.9. Nichi-Iko Pharmaceutical
11.10. Novo Holdings A/S
11.11. Zhejiang Hisun
11.12. Hengrui Medicine
11.13. Huadong Medicine
11.14. Civica Rx
12. APPENDIX
12.1. References
12.2. Related Reports
12.3. List of Abbreviation
NOTE:
This table of content is tentative and subject to change as the research progresses.
• In section 11, only the top ten companies will be profiled. Each company will be profiled based on the Market Overview, Financials, Product Portfolio, Business Strategies, and Recent Developments parameters.
• Please note: The financial details of the company cannot be provided if the information is not available in the public domain and or from reliable sources.
